Inflammatory Arthritis: What Adults Should Know

Inflammatory arthritis is an umbrella term for a group of joint diseases driven by immune system dysfunction rather than the mechanical wear-and-tear process of osteoarthritis. While OA accounts for the majority of arthritis diagnoses in adults over 50, inflammatory arthritis conditions — including rheumatoid arthritis, psoriatic arthritis, reactive arthritis, ankylosing spondylitis, and crystal arthropathies — represent distinct disease entities with their own mechanisms, clinical patterns, blood test profiles, and treatment approaches. For adults presenting with joint pain, swelling, or stiffness, understanding the difference between degenerative and inflammatory arthritis is the key to obtaining the right diagnosis and the right treatment.

The clinical hallmarks of inflammatory arthritis — prolonged morning stiffness, symmetrical joint involvement, systemic features such as fatigue and elevated inflammatory markers, and joint swelling that is soft and boggy rather than hard and bony — distinguish it from OA and should prompt urgent medical assessment. Inflammatory arthritis responds to anti-inflammatory and immunomodulatory treatments that have no place in OA management. The earlier inflammatory arthritis is identified and treated, the better the long-term outcome.

What Makes Arthritis “Inflammatory”?

The word inflammatory in inflammatory arthritis refers to the mechanism driving joint damage: immune-mediated synovial inflammation. In inflammatory arthritis, the synovial membrane — the tissue lining the inner surface of joints — is infiltrated by immune cells (T lymphocytes, B lymphocytes, macrophages) that produce pro-inflammatory cytokines including tumour necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6). These cytokines drive synovial hyperplasia, joint effusion, cartilage degradation, and — in sustained inflammation — bone erosion.

The cardinal clinical features of inflammation — redness (rubor), warmth (calor), swelling (tumor), pain (dolor), and loss of function (functio laesa) — are all present to varying degrees in inflammatory arthritis. The systemic inflammatory burden also produces fatigue, anaemia, and elevated acute phase proteins (CRP, ESR, ferritin). This systemic dimension is what distinguishes inflammatory from degenerative arthritis and what creates the cardiovascular and other systemic risks associated with rheumatoid and psoriatic arthritis.

Types of Inflammatory Arthritis

Rheumatoid Arthritis (RA)

The most common chronic inflammatory arthritis, affecting approximately 400,000 people in the UK. RA is a systemic autoimmune disease in which anti-CCP and rheumatoid factor autoantibodies are produced, attacking synovial membranes throughout the body. It characteristically affects MCP joints, PIP joints, and wrists symmetrically, with prolonged morning stiffness. Without DMARD treatment, RA causes progressive bone erosions and joint deformity. Modern treatment with methotrexate and biologic agents has dramatically improved long-term outcomes. Understanding rheumatoid arthritis symptoms and diagnosis is essential for recognising it early enough to benefit from the window of opportunity for treatment.

Psoriatic Arthritis (PsA)

An inflammatory arthritis associated with psoriasis, affecting approximately 1 in 3 people with psoriasis — around 100,000 people in the UK. PsA produces a wide spectrum of joint disease patterns, including peripheral arthritis (similar to RA but often asymmetrical and with DIP joint involvement), axial involvement (spinal inflammation similar to ankylosing spondylitis), dactylitis (“sausage digits” — swelling of an entire finger or toe), and enthesitis (inflammation at the attachment points of tendons and ligaments to bone). The skin psoriasis may precede, coincide with, or follow the joint involvement, and its severity does not predict the severity of the arthritis. Anti-CCP is usually negative; RF is typically negative.

Ankylosing Spondylitis and Axial Spondyloarthritis

A form of inflammatory arthritis primarily affecting the sacroiliac joints and spine, producing inflammatory back pain — worse at rest and in the morning, improving with activity — in young adults (peak onset 20–35 years). Males are affected 2–3 times more often than females in classic ankylosing spondylitis, though the gender ratio is more equal in non-radiographic axial SpA. HLA-B27 is present in over 90% of patients with ankylosing spondylitis. Progressive spinal fusion (bamboo spine) develops in untreated severe disease. Extra-articular features include anterior uveitis (acute eye inflammation), and peripheral large joint involvement can occur. Peripheral enthesitis and dactylitis are also features of axial SpA.

Reactive Arthritis

An inflammatory arthritis triggered by a bacterial infection elsewhere in the body — typically a urogenital infection (Chlamydia trachomatis) or gastrointestinal infection (Salmonella, Campylobacter, Shigella). It typically presents 1–4 weeks after the triggering infection, often without the infection itself being symptomatic. The classic Reiter’s triad (urethritis, conjunctivitis, and arthritis) is the complete syndrome but incomplete presentations are common. The arthritis is typically asymmetrical, affects large joints of the lower limb (knee, ankle), and is often associated with enthesitis and mouth ulcers. Most cases resolve within 6 months, though a proportion become chronic. HLA-B27 positivity is a risk factor for a more severe and persistent course.

Crystal Arthropathies: Gout and CPPD

Crystal arthropathies are caused by crystal deposition within joint spaces, triggering acute inflammatory responses. Gout is caused by monosodium urate crystal deposition, typically presenting as recurrent episodes of exquisitely painful acute arthritis in the first MTP joint (big toe), ankle, or knee — provoked by high serum uric acid levels from diet, alcohol, diuretic use, or chronic kidney disease. CPPD (calcium pyrophosphate deposition disease) produces acute pseudogout — typically in the knee — from calcium pyrophosphate crystal deposition, and can also cause a chronic polyarthritis mimicking RA. Crystal arthropathies are treated with different medications from autoimmune inflammatory arthritis (colchicine, NSAIDs, and allopurinol for gout; NSAIDs and colchicine for CPPD) and require crystal identification from joint fluid to confirm the diagnosis definitively.

Lupus (SLE)

Systemic lupus erythematosus is a multisystem autoimmune disease that commonly includes inflammatory arthritis as one of its features — typically non-erosive, affecting small joints of the hands and wrists. The diagnosis is made by a constellation of clinical features and autoantibody profile (ANA, anti-dsDNA) rather than joint involvement alone. Lupus arthritis is managed as part of the overall SLE treatment strategy.

Key Features That Identify Inflammatory Arthritis

Several clinical features — when present individually or in combination — should trigger assessment for inflammatory rather than degenerative arthritis:

• Morning stiffness lasting more than 30–60 minutes: The single most reliable discriminating feature. OA morning stiffness lasts under 30 minutes; inflammatory arthritis morning stiffness typically lasts over 60 minutes and may persist for several hours.
• Age under 45: OA is uncommon before 45 (except post-traumatic). Inflammatory arthritis (RA, SpA, PsA, reactive arthritis) frequently presents in young and middle-aged adults. New joint disease in adults under 45 deserves a lower threshold for inflammatory arthritis investigation.
• Systemic features: Fatigue, low-grade fever, weight loss, and malaise are not features of OA. Their presence alongside joint symptoms is a strong indicator of inflammatory arthritis.
• Symmetrical small joint involvement: Bilateral MCP or PIP joint swelling is characteristic of RA. Symmetry is more typical of inflammatory than degenerative disease, though early RA can be asymmetrical.
• Elevated CRP or ESR: Significantly elevated inflammatory markers are not explained by uncomplicated OA and indicate inflammatory joint or systemic disease.
• Joint warmth at rest: Warm joints at rest (rather than just after exercise) indicate active synovitis. OA joints may be warm during crystal flares but are not typically warm at rest as a persistent finding.
• Skin or nail changes: Psoriatic plaques or nail pitting alongside joint symptoms indicate psoriatic arthritis. A butterfly rash suggests lupus.
• Uveitis or eye redness: Anterior uveitis (painful eye redness with photophobia) is associated with ankylosing spondylitis, reactive arthritis, and IBD-related arthritis.

Investigations for Inflammatory Arthritis

When inflammatory arthritis is suspected, a structured set of blood tests and imaging enables the specific diagnosis:

• Blood tests: CRP and ESR (general inflammatory markers); full blood count (anaemia of chronic disease in RA, neutropenia in Felty’s); RF and anti-CCP (RA markers); ANA, anti-dsDNA (lupus); HLA-B27 (SpA, reactive arthritis); uric acid (gout — though normal uric acid during an acute attack does not exclude gout); urine microscopy and culture; STI screen where reactive arthritis is suspected.
• Imaging: X-rays of affected joints (baseline erosion assessment); MRI for early inflammatory changes not visible on X-ray; sacroiliac joint MRI when axial SpA is suspected; musculoskeletal ultrasound for synovitis assessment and injection guidance.
• Joint aspiration: Aspiration of acutely inflamed joints provides synovial fluid for crystal microscopy (confirming gout or CPPD), Gram stain and culture (excluding septic arthritis), and cell count (high WBC in inflammatory arthritis vs very high WBC in septic arthritis).

Any combination of prolonged morning stiffness, systemic features, and elevated inflammatory markers should prompt same-day or next-day medical assessment — ideally with urgent referral to rheumatology rather than a delayed routine appointment. The key differences between osteoarthritis and rheumatoid arthritis clarify when to suspect inflammatory disease in a patient presenting with joint pain.

Treatment Principles for Inflammatory Arthritis

Inflammatory arthritis is treated with agents that target the immune-inflammatory process, unlike OA where treatment is symptomatic:

• NSAIDs: Effective for pain and inflammation in all inflammatory arthritides but do not modify disease progression in RA or PsA. First-line for acute gout attacks and for symptom management in axial SpA.
• Corticosteroids: Powerful short-term anti-inflammatories used for flare management and bridging therapy. Not for long-term use as sole treatment due to metabolic, cardiovascular, and skeletal toxicity.
• Conventional DMARDs: Methotrexate, hydroxychloroquine, sulfasalazine, leflunomide — used in RA and PsA to halt disease progression. Not indicated for crystal arthropathy or reactive arthritis.
• Biologic DMARDs: Anti-TNF agents, IL-6 inhibitors, IL-17 inhibitors (particularly for PsA and AS), IL-23 inhibitors — used when conventional DMARDs fail. Highly effective in RA, PsA, and AS.
• Urate-lowering therapy: Allopurinol or febuxostat in gout — reduce serum uric acid to target (<300 µmol/L) to prevent crystal formation. Long-term maintenance therapy in recurrent gout.

Inflammatory Arthritis and Pregnancy

Inflammatory arthritis has important interactions with pregnancy that both patients and their clinicians need to be aware of:

• RA and pregnancy: Many women with RA experience significant improvement in symptoms during pregnancy — possibly related to the immunological adaptations of pregnancy that shift immune responses toward tolerogenic pathways. However, the majority experience a post-partum flare in the weeks to months after delivery as immune function returns to normal. Planning pregnancy with the rheumatology team is important: methotrexate, leflunomide, and mycophenolate are teratogenic and must be stopped before conception (methotrexate: at least 3 months before, with folic acid supplementation). Hydroxychloroquine and sulfasalazine are generally considered compatible with pregnancy. Most biologic DMARDs are used on a case-by-case basis depending on the agent — some anti-TNF agents cross the placenta in the third trimester, which has implications for the timing of the baby’s live vaccines after birth.
• Psoriatic arthritis and pregnancy: PsA often improves during pregnancy but the evidence is less consistent than for RA. The same DMARD safety considerations apply as for RA regarding teratogenic agents.
• Axial SpA and pregnancy: Women with axial SpA may experience worsening of peripheral joint and axial symptoms during pregnancy, particularly in the third trimester when sacroiliac joint laxity increases. Delivery planning should consider spinal flexibility (epidural access may be affected by severe spinal disease) and, for those on anti-TNF therapy, the implications of third-trimester treatment on neonatal vaccination schedules.
• Gout in pregnancy: Uncommon in women of reproductive age. Allopurinol use in pregnancy has an uncertain safety profile — it is generally discontinued during pregnancy if possible, and attacks during pregnancy are managed with low-dose prednisolone or colchicine (which has evidence for safety in pregnancy from familial Mediterranean fever studies).

Inflammatory Arthritis and the Gut: The Microbiome Connection

An emerging and clinically significant area of inflammatory arthritis research is the relationship between the gut microbiome and systemic inflammatory joint disease. Multiple lines of evidence support a pathogenic role of gut dysbiosis (altered microbiome composition) in inflammatory arthritis:

• RA and the gut: Several studies have demonstrated differences in gut microbiome composition between newly diagnosed RA patients and healthy controls, including depletion of certain beneficial bacteria (Bifidobacterium, Lactobacillus) and enrichment of potentially pathogenic species. The oral microbiome — particularly Porphyromonas gingivalis — has been specifically linked to anti-CCP antibody generation through citrullination of bacterial proteins that cross-react with human joint proteins. This may partly explain the well-established association between periodontal disease and RA.
• Spondyloarthritis and the gut: Axial SpA has a particularly strong gut-joint axis. Approximately 60% of SpA patients have subclinical gut inflammation on ileocolonoscopy, and 10% develop clinical inflammatory bowel disease (IBD — Crohn’s or ulcerative colitis) during their disease course. The gut and joint inflammation appear to share pathogenic mechanisms involving innate immune activation, and IL-17 inhibitors (effective in both SpA and inflammatory bowel disease) represent therapeutic exploitation of this shared biology.
• Reactive arthritis and the gut: The causative mechanism of reactive arthritis explicitly involves bacterial translocation — gut bacterial antigens triggering immune responses that cross-react with joint tissues. This is the clearest example of a direct gut-to-joint inflammatory pathway.

While microbiome manipulation (probiotics, dietary modification) has not yet demonstrated consistent clinical benefit in inflammatory arthritis, this area is active in research and may produce practical interventions in coming years.

Living with Inflammatory Arthritis: Practical Considerations

Managing inflammatory arthritis extends well beyond medication. Several practical strategies improve daily life and long-term outcomes:

• Exercise: All forms of inflammatory arthritis benefit from tailored exercise that maintains joint range of motion, muscle strength, and cardiovascular fitness. During flares, gentle range-of-motion exercises maintain mobility. During remission, structured strengthening and aerobic programmes should be pursued. Hydrotherapy (exercise in a warm pool) is particularly useful when land-based exercise is too painful. Muscle weakness and fatigue accompanying joint symptoms are common in inflammatory arthritis and are addressed through rehabilitation alongside disease-modifying treatment.
• Sleep and fatigue management: Fatigue is one of the most impactful and least-addressed symptoms of inflammatory arthritis. Strategies include: sleep hygiene optimisation, pacing activity to avoid post-exertional flares, cognitive behavioural therapy for fatigue (evidence-based in RA), and addressing nocturnal pain through appropriate analgesic adjustment. Fatigue that persists despite well-controlled disease activity should prompt assessment for comorbid depression, sleep apnoea, or anaemia.
• Smoking cessation: Smoking is both a risk factor for developing RA and a factor that worsens disease severity, reduces DMARD response rates, and increases cardiovascular and pulmonary complications. Smoking cessation is one of the most impactful self-management steps a person with inflammatory arthritis can take.
• Vaccination: People on immunosuppressive DMARDs and biologics have increased infection susceptibility. Annual influenza vaccine, pneumococcal vaccine, and (before starting biologic therapy) shingles vaccination are recommended. Live vaccines (including BCG, measles-mumps-rubella, yellow fever) are generally contraindicated during immunosuppressive treatment — timing of live vaccines must be planned before therapy begins.
• Patient education and self-management support: Arthritis UK (Versus Arthritis) and NRAS (National Rheumatoid Arthritis Society) provide structured self-management programmes, telephone helplines, and peer support networks that improve patient outcomes independently of medication management.

When to Seek Urgent Review for Inflammatory Arthritis

Certain presentations associated with inflammatory arthritis require same-day or emergency medical review rather than a routine GP appointment. A hot, swollen single joint with fever is a medical emergency until septic arthritis (joint infection) has been excluded by joint aspiration — septic arthritis is limb- and life-threatening if not treated immediately with joint washout and antibiotics. Acute eye redness with pain and photophobia in a patient with inflammatory arthritis suggests anterior uveitis requiring same-day ophthalmology review — untreated acute anterior uveitis can cause permanent visual loss. Sudden severe neck pain with neurological symptoms (arm weakness or tingling) in a patient with established RA raises the possibility of atlanto-axial subluxation — a neurosurgical emergency requiring immediate imaging. These complications are rare but their consequences are severe enough to warrant immediate action when the clinical picture is consistent. For all other presentations of suspected inflammatory arthritis, urgent GP assessment with rheumatology referral within days to weeks is the appropriate standard of care.

Key Resources

• NHS: Rheumatoid Arthritis
• Versus Arthritis: Types of Arthritis
• NICE NG100: Rheumatoid Arthritis in Adults

Frequently Asked Questions

What is inflammatory arthritis?

Inflammatory arthritis is a group of joint diseases caused by immune system dysfunction, in which immune cells attack the synovial lining of joints producing inflammation, swelling, and — if untreated — joint damage. Unlike osteoarthritis (which is driven by cartilage wear and bone remodelling), inflammatory arthritis has a primary immune mechanism that responds to anti-inflammatory and immunomodulatory treatments. Types include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, reactive arthritis, gout, and CPPD. The hallmarks are prolonged morning stiffness, soft synovitic swelling, fatigue, and elevated inflammatory markers.

What is the most common type of inflammatory arthritis?

Rheumatoid arthritis is the most common chronic inflammatory arthritis, affecting approximately 400,000 people in the UK and around 18 million worldwide. Gout is the most common acute inflammatory arthritis, affecting approximately 1 in 40 adults in the UK with recurrent episodes of acute joint inflammation from urate crystal deposition. Psoriatic arthritis affects approximately 1 in 3 people with psoriasis — a prevalence of around 100,000 in the UK. Ankylosing spondylitis affects approximately 200,000 people in the UK, predominantly young men.

Is inflammatory arthritis the same as rheumatoid arthritis?

No — inflammatory arthritis is a broader category that includes rheumatoid arthritis as one of its members. RA is the most common chronic inflammatory arthritis, but the category also includes psoriatic arthritis, ankylosing spondylitis, reactive arthritis, gout, CPPD disease, lupus arthritis, and other autoimmune arthritis conditions. Each has its own specific mechanism, clinical pattern, autoantibody profile, and treatment approach. Diagnosing which type of inflammatory arthritis is present is important because, for example, RA requires methotrexate-based DMARDs while gout requires urate-lowering therapy — these treatments are not interchangeable.

How do I know if I have inflammatory arthritis?

Features suggesting inflammatory rather than degenerative arthritis include: morning joint stiffness lasting more than 30–60 minutes; joint swelling that is soft and warm (not bony); fatigue out of proportion to activity; involvement of multiple small joints (particularly MCP and PIP joints) or symmetrical joint involvement; age under 45; and elevated CRP or ESR on blood testing. If these features are present, medical assessment is needed — the specific type of inflammatory arthritis requires further testing by a GP and likely rheumatology referral to define.

Can inflammatory arthritis be cured?

Most forms of inflammatory arthritis are not currently curable — the autoimmune or metabolic process that drives them cannot be permanently switched off. However, modern treatments achieve sustained remission or low disease activity in the majority of patients with RA and PsA when treatment is started early and managed proactively. Gout — the major exception — is effectively cured when urate-lowering therapy reduces serum uric acid to below the crystal saturation threshold: crystals dissolve over months to years, and attacks cease in most patients who maintain adequate urate lowering. Reactive arthritis resolves completely in most cases within 6 months of the triggering infection being treated.

References

1. Smolen JS, et al. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038.
2. Ritchlin CT, et al. Psoriatic arthritis. N Engl J Med. 2017;376(10):957–970.
3. NICE. Spondyloarthritis in over 16s: diagnosis and management. NG65. 2017.
4. Dougados M, Baeten D. Spondyloarthritis. Lancet. 2011;377(9783):2127–2137.
5. Richette P, Bardin T. Gout. Lancet. 2010;375(9711):318–328.
6. NHS. Types of arthritis. nhs.uk. Updated 2023.
7. NICE. Rheumatoid arthritis in adults: management. NG100. 2018.
8. Zeidler H, et al. Reactive arthritis. Best Pract Res Clin Rheumatol. 2011;25(3):347–357.